Medeon Biodesign - Asset Resilience Ratio
Medeon Biodesign (6499) has an Asset Resilience Ratio of 45.44% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Medeon Biodesign (6499) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Medeon Biodesign's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Medeon Biodesign (6499) total assets.
Liquid Assets Composition Over Time
This chart breaks down Medeon Biodesign's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 6499 current and long-term liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$763.08 Million | 45.44% |
| Total Liquid Assets | NT$763.08 Million | 45.44% |
Asset Resilience Insights
- Very High Liquidity: Medeon Biodesign maintains exceptional liquid asset reserves at 45.44% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Medeon Biodesign Industry Peers by Asset Resilience Ratio
Compare Medeon Biodesign's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Qingdao NovelBeam Technology Co. Ltd. A
SHG:688677 |
Medical Instruments & Supplies | 2.66% |
|
Autek China Inc
SHE:300595 |
Medical Instruments & Supplies | 21.20% |
|
St.Shine Optical Co Ltd
TWO:1565 |
Medical Instruments & Supplies | 1.28% |
|
Safe Orthopaedics SA
PA:ALSAF |
Medical Instruments & Supplies | 2.20% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 7.53% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 46.84% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 3.36% |
|
Austco Healthcare Ltd
AU:AHC |
Medical Instruments & Supplies | 15.90% |
Annual Asset Resilience Ratio for Medeon Biodesign (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Medeon Biodesign.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 39.28% | NT$699.07 Million ≈ $22.02 Million |
NT$1.78 Billion ≈ $56.07 Million |
+2.33pp |
| 2024-12-31 | 36.95% | NT$693.84 Million ≈ $21.86 Million |
NT$1.88 Billion ≈ $59.16 Million |
+4.04pp |
| 2023-12-31 | 32.91% | NT$904.03 Million ≈ $28.48 Million |
NT$2.75 Billion ≈ $86.55 Million |
+6.59pp |
| 2022-12-31 | 26.32% | NT$1.06 Billion ≈ $33.50 Million |
NT$4.04 Billion ≈ $127.28 Million |
-10.67pp |
| 2021-12-31 | 36.99% | NT$1.61 Billion ≈ $50.87 Million |
NT$4.36 Billion ≈ $137.51 Million |
+5.07pp |
| 2020-12-31 | 31.92% | NT$1.06 Billion ≈ $33.34 Million |
NT$3.31 Billion ≈ $104.42 Million |
-20.85pp |
| 2019-12-31 | 52.77% | NT$1.33 Billion ≈ $41.85 Million |
NT$2.52 Billion ≈ $79.30 Million |
-1.65pp |
| 2018-12-31 | 54.42% | NT$1.06 Billion ≈ $33.39 Million |
NT$1.95 Billion ≈ $61.35 Million |
+5.56pp |
| 2017-12-31 | 48.86% | NT$800.44 Million ≈ $25.22 Million |
NT$1.64 Billion ≈ $51.61 Million |
-- |
About Medeon Biodesign
Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular g… Read more